IDO1-targeting polypeptide and IDO1 protein degradation targeting chimera
High-affinity IDO1 peptides were screened through phage display technology and combined with components such as thalidomide to construct IDO1 protein degradation chimera, solving the problem of targeted degradation of IDO1 and achieving efficient anti-tumor treatment, especially in Gastric cancer has shown excellent therapeutic effects.
Patent Information
- Application Number
- CN202411107366.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-13
AI Technical Summary
The prior art has not yet established a protein degradation-targeted chimera that can be effectively applied to IDO1 targeted degradation, and it is difficult to screen out high-affinity IDO1 ectodomain protein-binding polypeptides.
The phage display technology was used to screen out IDO1 ectodomain protein-binding peptides with high affinity and bind to the E3 ubiquitin ligase ligand thalidomide to design and construct IDO1 protein degradation targeted chimera (PROTAC) through linkers Components such as PEG2 and membrane-penetrating peptide R8 form effective targeting agents.
Successfully obtained high-affinity polypeptide Q1, strong binding power, low cost, high recognition efficiency, can effectively degrade IDO1, provide more selective anti-tumor drugs, especially in the treatment of gastric cancer, showing good therapeutic efficiency and reducing the whole body The effect of toxicity.
Smart Images

Figure CN118994316A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biological medicines, and in particular relates to a polypeptide targeting IDO1 and an IDO1 protein degradation targeting chimera. Background Art
[0002] Indoleamine-2,3-dioxygenase 1 (IDO1) is an oxidoreductase composed of 403 amino acids and heme. It contains an active site and is the rate-limiting enzyme of the kynurenine pathway. Through the kynurenine pathway, IDO1 can catalyze the metabolism of tryptophan to produce cytotoxic metabolites such as kynurenine and quinolinic acid. Under normal circumstances, the expression level of IDO1 in the body is low. Recent studies have shown that IDO1 is expressed at a high level in a variety of tumor tissues, and its expression level is also positively correlated with the poor prognosis of a variety of cancers. In addition, IDO1 has been proven to be related to tumor immune escape, and is also closely related to a variety of major human diseases (such as cataracts, Alzheimer's disease, etc.). Further studies have shown that IDO1 plays an important immunoregulatory role in immunoregulation such as suppressing T cell immunity, anti-tumor immunity, and tumor immune escape. Therefore, using IDO1 purified protein as a drug target to screen affinity peptides is of great significance for the prevention and treatment of tumors.
[0003] The proteolysis targeting chimera (PROTAC) is a bifunctional molecule, also known as a heterobifunctional degrader, which consists of three parts: a ligand that binds to the target protein, an E3 ubiquitin ligase ligand, and a linker that connects the two. PROTAC can bind to the target protein at one end and bind to the E3 ligase at the other end to form a ternary complex. The E3 ligase and the target protein are spatially adjacent to each other, mediating the ubiquitination of the target protein by the E2 conjugated enzyme; subsequently, the proteasome recognizes and degrades the ubiquitinated target protein. In theory, PROTAC molecules only provide binding activity, which is an "event-driven" mode of action. It does not require long-term high-intensity binding to the target protein, so it can be recycled repeatedly. Compared with traditional “occupancy-driven” drugs, PROTAC molecules have the following advantages: (1) They provide a new type of rapid and reversible chemical knockout method; (2) They make difficult-to-drug targets druggable; (3) They reduce drug toxicity and side effects; (4) They enable targets that are prone to drug-resistant mutations in clinical practice to maintain long-term sensitivity; and (5) They can affect non-enzyme activity functions by degrading the entire protein.
[0004] It can be seen that protein degradation targeted chimeras, as an emerging treatment method, have many advantages over traditional small molecule drugs. However, protein degradation targeted chimeras that can be effectively applied to IDO1 targeted degradation have not yet been established in the existing technology. Therefore, how to screen a high-affinity IDO1 extracellular domain protein binding polypeptide and successfully construct a proteolysis targeted chimera that can be used for IDO1 degradation has become a key problem that needs to be solved in this field. Summary of the invention
[0005] In order to solve the above-mentioned problems of the prior art, the first purpose of the present invention is to provide a polypeptide targeting IDO1, which is an affinity polypeptide targeting IDO1 obtained by successful selection using phage display technology in the present invention, and can effectively bind to E3 ubiquitin ligase ligands, thereby being used for the preparation of anti-tumor drugs targeting IDO1.
[0006] The second object of the present invention is to provide the use of the above-mentioned polypeptide targeting IDO1.
[0007] The third object of the present invention is to provide an IDO1 protein degradation targeting chimera.
[0008] The fourth object of the present invention is to provide the application of the above-mentioned IDO1 protein degradation targeting chimera.
[0009] The above technical purpose of the present invention is achieved by adopting the following technical solutions:
[0010] A polypeptide targeting IDO1, wherein the amino acid sequence of the polypeptide targeting IDO1 is shown in SEQ ID No. 1. Specifically, the amino acid sequence shown in SEQ ID No. 1 is PISFDLAQPSGQ.
[0011] The polypeptide targeting IDO1 provided by the present invention is a high-affinity and targeted IDO1 extracellular domain protein binding polypeptide successfully selected by phage display technology. Phage display technology is a technology in which an exogenous DNA fragment encoding a target protein or polypeptide is fused with a coding gene of a phage surface protein, and then presented on the surface of the phage in the form of a fusion protein. The displayed protein or polypeptide can maintain a relative spatial structure and biological activity and be displayed on the surface of the phage. The present invention is screened by phage display technology to obtain a phage clone with high affinity to the IDO1 extracellular domain protein, and then enriched by two rounds of panning, DNA extracted and sequenced, and a 12-peptide is successfully obtained, and its amino acid sequence is: PISFDLAQPSGQ, named Q1, and the polypeptide can be combined with a therapeutic drug as a targeting functional group, making the therapeutic drug for cancer disease more selective, while reducing systemic toxicity and providing higher therapeutic efficiency.
[0012] An application of the above-mentioned polypeptide targeting IDO1 in the preparation of anti-tumor drugs.
[0013] As a preferred embodiment, the anti-tumor drug is an anti-gastric cancer drug.
[0014] A chimera targeting IDO1 protein degradation is mainly prepared from the polypeptide targeting IDO1, thalidomide, a linker and a cell-penetrating peptide R8.
[0015] The present invention screens polypeptides with high affinity and targeting to IDO1, uses them as target protein ligands of IDO1, and rationally designs them with a specific E3 ubiquitin ligase ligand (thalidomide), synthesizes IDO1 protein targeting chimeras (PROTACs) for the first time, and evaluates their activity in cells, confirming that the constructed PROTACs can be effectively used in the preparation of anti-tumor drugs, especially anti-gastric cancer drugs, targeting IDO1.
[0016] As a preferred embodiment, the linker is PEG2. The length and composition of the linker play a key role in the biological activity and physicochemical properties of PROTAC. Linker is essential for helping the spatial orientation and positioning of E3 ligase and target protein to ensure favorable protein-protein interaction (PPI). The present invention uses two units of polyethylene glycol groups as connecting arms, because: 1) amphiphilic polyethylene glycol (PEG) is selected as a linker because it has good ductility in both hydrophobicity and hydrophilicity. 2) In addition, SAR data show that the active site of IDO1 is located in a deep cavity, and the distance from the amino group at the connection site to the external interface is >10A / cm. The difference in binding mode may affect the trajectory and optimal length of the linker motif. In the IDO1-PROTAC of the present invention, the polypeptide Q1 is used as the IDO1 targeting ligand. Compared with small molecules, the volume of the polypeptide itself is larger. If the linker remains longer, the volume of PROTAC increases, and the expansion of the molecule often inevitably leads to a significant decrease in affinity for IDO1. In order to make the PROTAC with thalidomide as the ligand of the CRBNE3 ligase closer to the "drug-like" space, its average hydrogen bond donor and clogP value fall within the boundaries of the drug-like Rule of 5 due to the unique starting properties of the E3 ligase warhead. Therefore, the present invention shortens the linker to 2 PEGs after the experiment.
[0017] As a preferred solution, the raw materials used in the preparation of the IDO1 protein degradation targeted chimera also include lysine.
[0018] As a preferred solution, the structure of the cell-penetrating peptide R8 is:
[0019]
[0020] As a preferred solution, the structure of the IDO1 protein degradation targeting chimera is:
[0021]
[0022] The application of the above-mentioned IDO1 protein degradation targeting chimera in the preparation of anti-tumor drugs.
[0023] As a preferred embodiment, the anti-tumor drug is an anti-gastric cancer drug.
[0024] Compared with the prior art, the beneficial effects of the present invention are mainly:
[0025] The present invention uses phage display technology for the first time to screen out an IDO1 extracellular domain protein binding polypeptide Q1 with high affinity. The polypeptide has a strong binding force with the IDO1 extracellular domain structural protein and has the characteristics of low cost, high sensitivity, high recognition efficiency and small molecular weight.
[0026] Furthermore, the present invention obtains PROTAC by rationally designing the above-mentioned polypeptide Q1 and the E3 ubiquitin ligase ligand thalidomide. Among them, since the molecular weight of the CRBN ligand is smaller than that of the VHL ligand, the number of rotatable bonds and hydrogen bond donors is small, it has better pharmacokinetic (PK) characteristics and higher blood-brain barrier (BBB) permeability, the present invention selects the CRBN ligand thalidomide as the target head at one end of PROTAC. The CRBN-E3 ligase-based PROTAC designed by the present invention with thalidomide or its derivatives as the E3 ligase ligand is closer to the "drug-like" space, and its average hydrogen bond donor and clogP value fall within the boundaries of Lipinski's "5-point rule", thereby giving the E3 ligase warhead a unique starting property. In addition, the present invention shortens the linker to 2 PEG units, wherein the high-affinity polypeptide Q1 is used as an IDO1 ligand, and the branched chain increases the ability of the membrane-penetrating peptide to enter the cell. Experiments have confirmed that the PROTAC designed by the present invention has good cell entry ability and IDO1 targeted degradation ability, which can provide new treatment strategies and effective technical support for the development of new tumor targeted drugs, especially anti-gastric cancer drugs and the treatment of related cancers. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is a schematic diagram of the structure of the IDO1 protein hydrolysis targeting chimera provided in Example 2 of the present invention;
[0028] Figure 2 The ELISA test results of the bacteriophage in the first test example of the present invention;
[0029] Figure 3aThis is the binding and dissociation curve of polypeptide Q1 and IDO1 extracellular domain protein verified by BLI biomembrane interference technology in Experimental Example 2 of the present invention;
[0030] Figure 3b The KD value and the fitting curve constant R calculated by the BLI biomembrane interference technology to verify the binding dissociation curve between the polypeptide Q1 and the IDO1 extracellular domain protein in the second test example of the present invention 2 ;
[0031] Figure 3c This is the binding and dissociation curve of polypeptide Q8 and IDO1 extracellular domain protein verified by BLI biomembrane interference technology in Experimental Example 2 of the present invention;
[0032] Figure 3d The KD value and the fitting curve constant R calculated by the BLI biomembrane interference technology to verify the binding dissociation curve of polypeptide Q8 and IDO1 extracellular domain protein in Experimental Example 2 of the present invention 2 ;
[0033] Figure 4 This is the result of IP verification of the binding of polypeptide Q1 to IDO1 protein in Experimental Example 3 of the present invention;
[0034] Figure 5 This is the concentration-dependent test result of the IDO1-PROTAC biological activity evaluation in Experimental Example 4 of the present invention;
[0035] Figure 6 This is the time-dependent test result of the IDO1-PROTAC biological activity evaluation in Experimental Example 4 of the present invention. DETAILED DESCRIPTION
[0036] In order to make the technical purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the accompanying drawings and Examples. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the scope of protection of the present invention. In the following examples, the raw materials or reagents involved are conventional materials or reagents that can be obtained through commercial channels unless otherwise specified.
[0037] Among them, the materials such as thalidomide, cell-penetrating peptide R8, and lysine involved in the following examples are from Shanghai Chupeptide Biotechnology Co., Ltd.
[0038] The preparation method of the LB liquid culture medium involved in the following examples is as follows: weigh 15g of sodium chloride, 15g of tryptone, and 7.5g of yeast extract into a 2L conical flask, add 1.5L of pure water, sterilize at 121°C, take out and place in a cold room for use.
[0039] The 20% polyethylene glycol / 2.5M sodium chloride solution involved in the following examples is prepared as follows: accurately weigh 10g PEG-8000 and 7.3g sodium chloride powder, add 50mL ultrapure water, sterilize under high pressure, turn the solution upside down while it retains residual temperature to mix the ingredients evenly, and store at room temperature.
[0040] The preparation method of the IDO1 protein involved in the following examples is as follows: obtaining the IDO1 gene sequence (IDO1 gene is located at nucleotides 39913891 to 39928790 of NC_000008; Homo sapiens chromosome 8, GRCh38.p14Primary Assembly-Nucleotide-NCBI (nih.gov)), constructing a pET-28a(+)-IDO1 prokaryotic expression vector containing a histone (His) tag, and then transfecting the vector into an E. coli.BL21 (DE3) Escherichia coli expression strain to obtain a strain that highly expresses IDO1, selecting positive clone colonies on a culture plate containing kanamycin resistance, amplifying them, adding IPTG to induce the expression of IDO1, and then using a cell ultrasonic disruptor to extract the total protein in the strain. Finally, according to the properties of the His tag, the imidazole-nickel affinity column purification system was used to separate and purify the IDO1 protein with a high purity (concentration of 6.66 μg / μL) for subsequent experiments.
[0041] Example 1
[0042] This embodiment provides a polypeptide targeting IDO1, whose amino acid sequence is PISFDLAQPSGQ (as shown in SEQ ID No. 1).
[0043] The above-mentioned peptide targeting IDO1 is screened by the following method:
[0044] 1. Enrichment of phages
[0045] (1) Fixation of IDO1 protein
[0046] Step 1-1: Prepare IDO1 protein. Use 0.1M NaHCO3 solution (pH8.6) to prepare IDO1 protein solution with a final concentration of 10-100μg / mL. Prepare a sterile ELISA plate (maximum range of 200uL per well), add 150uL of the diluted IDO1 protein solution, seal it, and incubate it overnight at 4℃ with slight shaking;
[0047] Step 1-2: Prepare sterile paper towels, turn the sterile ELISA plate upside down and tap it gently to remove the residual NaHCO3 solution;
[0048] Step 1-3: Prepare TBST buffer (TBS+0.1% (v / v) Tween-20) and quickly wash the wells 6 times.
[0049] (2) First round of selection
[0050] Step 2-1: Prepare PH.D TM .-12 phage display peptide library kit (New England Biolabs, USA), take 1uL of phage and dilute it into 99uL of TBST buffer, incubate it in the empty well without protein fixation at room temperature for 30min, aspirate the solution and add it to the well with IDO1 protein fixed and washed, and incubate it at room temperature for 30min;
[0051] Step 2-2: Invert the plate on a sterile paper towel, pour out the unbound phage, and wash the plate 10 times with 150uLTBST buffer as described in step 1-3. Use a clean paper towel each time to prevent cross contamination;
[0052] Step 2-3: Prepare elution buffer (0.2M glycine-HCl buffer, pH 2.2), pipette 100uL into the well treated in the previous step, shake gently for 10 minutes, pipette the eluate into a 200uL centrifuge tube, and neutralize with 30uL neutralization buffer (1M Tris-HCl, pH 9.1).
[0053] (3) Titer determination before the first round of panning amplification
[0054] Step 3-1: Use sterilized LB liquid medium (add 5 μg / mL tetracycline) to gradiently dilute the first round of panning eluate obtained in step 2-3, with the dilution multiples of 10 1 , 10 2 , 10 3 , 10 4 ;
[0055] Step 3-2: Take 10uL and 200uL of E. coli ER2738 strain (OD 600 =0.5) culture was mixed, incubated for 1-5 min, 3 mL of 45°C top agar solution (5 μg / mL of tetracycline added) was added, mixed evenly and then spread on an IPTG / Xgal titration plate, incubated in dark for 14-16 h. The results are shown in Table 1.
[0056] Table 1. Titer determination before the first round of panning amplification of IDO1-phage screening
[0057]
[0058] When performing each round of phage panning, the eluted phage solution and the amplified phage solution need to be titered to confirm the amount of phage to be added in the next round. During titer determination, only when the multiplicity of infection (MOI) is much less than 1, that is, when there is a large excess of host cells, will the phage plaques formed when the phage infects the host cells increase linearly with the addition of phage. Therefore, the present invention dilutes the phage solution before infecting Escherichia coli, and at the same time, it can also ensure that the formed phage plaques contain only one DNA sequence.
[0059] The lacZ gene is a structural gene of the lac operon in Escherichia coli, responsible for expressing β-galactosidase. The gene encoding the α fragment of β-galactosidase in ER2738 Escherichia coli is missing, so that the activity of β-galactosidase is lost. When the phage carrying the lacZ (α fragment) of the lac operon infects ER2738, under the action of IPTG, the α fragment of β-galactosidase is successfully expressed, and the activity of β-galactosidase is restored, which can decompose X-gal to produce blue metabolites. Therefore, after the modification, the M13 phage carrying the twelve peptide will form blue plaques on the IPTG / X-gal plate after infecting the ER2738 host bacteria. The present invention determines the titer of the phage solution by counting the blue plaques on the plate, while the wild-type phage does not have this effect, and forms white plaques on the IPTG / X-gal plate. The white plaques are the key factor for quality control in the entire panning process of the present invention.
[0060] When titer was measured, the optimal dilution was about 100 blue plaques on the solid culture medium. As shown in Table 1, the titer before amplification was 1.3×10 4 pfu / μL.
[0061] (4) First round of phage amplification and purification
[0062] Step 4-1: Add 20 mL of Escherichia coli ER2738 strain D to the first round of eluate 600 =0.01-0.05) culture, and cultured at 37°C, 220 rpm for 4.5 h;
[0063] Step 4-2: Transfer the culture to a 10 mL centrifuge tube, centrifuge at 12,000 g for 10 min at 4 °C, transfer the supernatant to a new centrifuge tube, and centrifuge at 12,000 g for 10 min at 4 °C;
[0064] Step 4-3: Transfer 80% of the supernatant to a new centrifuge tube, add 1 / 6 volume of 20% polyethylene glycol / 2.5 M sodium chloride solution, and let stand at 4°C overnight;
[0065] Step 4-4: Incubate the polyethylene glycol precipitate obtained in step 4-3 on ice for 15-60 minutes, centrifuge at 4°C and 12000g for 15 minutes, discard the supernatant, resuspend, and completely discard the remaining supernatant. At this time, a white film on the wall of the centrifuge tube is the phage particles;
[0066] Step 4-5: Suspend the phage particles obtained in the previous step in 200 μL of TBS buffer and transfer to a 200 μL centrifuge tube to obtain the eluate after the first round of amplification.
[0067] (5) Titer determination after the first round of panning amplification
[0068] Step 5-1: Use sterilized LB liquid medium (add 5 μg / mL tetracycline) to gradient dilute the first round of panning eluate, the dilution multiples are 10 9 , 10 10 , 10 11 , 10 12 ;
[0069] Step 5-2: Take 10uL of each gradient dilution and mix with 200uL of E. coli ER2738 strain (OD 600 =0.5) culture, incubate for 1-5 min, add 3 mL of 45°C top agar solution (add 5 μg / mL tetracycline), mix well and spread on IPTG / Xgal titration plate, incubate in dark for 14-16 h. The results are shown in Table 2. At this point, the first round of panning and enrichment is completed.
[0070] Table 2. Titer determination after the first round of panning amplification of IDO1-phage screening
[0071]
[0072] After obtaining the titer after the first round of amplification, the volume of phages of the same order of magnitude as in the first round was calculated according to the titer to carry out the second round of panning. The purpose of gradient dilution is to ensure that the number of blue spots on the solid culture medium can be within 100, because within 100 is the best dilution and the titer is most accurate. As shown in Table 2, the titer after the first round of amplification is 1.08×10 12 pfu / μL, according to the first round of amplification before the input 1×10 10 pfu phage, the second round needs to invest 1×10 10 / 1.08×10 12 =0.00925 μL of amplified phage eluate.
[0073] (6) Second round of selection
[0074] Step 6-1: Count the blue plaques on the IPTG / Xgal titer plate and determine the titer of the phage after amplification. The titer after the first round of amplification is 1.08×10 12 pfu / μL. Use this value to calculate the input volume corresponding to the input titer in step 2-1, add it to the wells with fixed IDO1 protein, and incubate at room temperature for 30min-60min; step 6-2: same as step 2-2; step 6-3: same as step 2-3.
[0075] (7) Titer determination before the second round of panning amplification
[0076] Step 7-1: Use sterilized liquid culture medium to dilute the second round of panning eluate in a gradient manner, with a dilution factor of 10 1 , 10 2 , 10 3 , 10 4 Step 7-2: Same as step 3-2. The titer determination results are shown in Table 3.
[0077] Table 3. Titer determination before the second round of panning amplification of IDO1-phage screening
[0078]
[0079] As shown in Table 3, the titer before amplification was 5 pfu / μL.
[0080] (8) Second round of phage amplification and purification
[0081] Step 8-1: Add 20 mL of Escherichia coli ER2738 (OD 600 =0.01-0.05), culture at 37°C, 220rpm for 4.5h; Steps 8-2, 8-3, 8.4: the same as steps 4-2, 4-3, 4-4; Step 8-5: suspend the phage particles in 200μL TBS phage, transfer to a 200μL centrifuge tube, and obtain the eluate after the second round of amplification.
[0082] (9) Titer determination after the second round of panning amplification
[0083] Step 9-1: Use sterilized liquid culture medium to dilute the second round of panning eluate in a gradient manner, with a dilution factor of 10 9 , 10 10 , 10 11 , 10 12 ;
[0084] Step 9-2: Same as step 5-2. The titer test results are shown in Table 4. At this point, the second round of panning and enrichment is completed.
[0085] Table 4. Titer determination after the second round of panning amplification of IDO1-phage screening
[0086]
[0087] As shown in Table 4, the titer after the first round of amplification was 1.33×10 10 pfu / μL.
[0088] (10) Select blue spots and sequence
[0089] Step 10-1: Add 300uL of Escherichia coli ER2738 strain (D600 = 0.01-0.05) culture to a 1.5mL centrifuge tube, pick up 10 blue spots after the second round of panning amplification with a sterile pipette tip and add them to the centrifuge tube respectively, stir, amplify for 4.5h until the solution becomes turbid, and then use high-throughput sequencing to identify USP7 specifically binding to the phage twelve peptide;
[0090] Step 10-2: Analyze the sequencing results. A large number of repeated sequences prove that the phage has been initially enriched.
[0091] The process of high-throughput sequencing to identify USP7 specifically binding to phage twelve peptides is as follows:
[0092] After two rounds of panning of the phage random twelve-peptide library, the DNA of the last round of eluted phage was extracted respectively, and the DNA fragment containing the specific twelve-peptide sequence was PCR amplified by the designed primers, and then the amplified target fragment was sent to Beijing Qingke Biotechnology Co., Ltd. for library construction and high-throughput sequencing. The high-throughput sequencing results were further analyzed, and the sequencing results are shown in Table 5. In Table 5, "empty" represents the polypeptide sequence resolved from the background spot (monoclonal colony), which is a non-specific binding twelve-peptide sequence.
[0093] Table 5. Amino acid sequences of IDO1-specifically binding phage dodecapeptide
[0094]
[0095] As shown in Table 5, a total of 62720 dodecapeptide sequences specifically binding to IDO1 were obtained, among which the sequence with the highest frequency of specific binding among the dodecapeptides was the Q1 sequence, followed by the Q8 sequence.
[0096] In the above screening process, the present invention selects the extracellular domain IDO1 as the panning source, and uses the phage random 12 peptide library to pan the specific binding polypeptide of the immune checkpoint IDO1. The specifically bound polypeptide is obtained by continuous biological panning and enrichment. Biological panning refers to the phage library and the target protein molecule after a certain period of incubation, washing away the unbound free phage to compete for the receptor or acid elution with the target molecule. The adsorbed phage. After the eluted phage infects the host, the next round of elution is carried out after reproduction and amplification. After 3-5 rounds of "adsorption, elution-amplification", the phage that specifically binds to the target molecule is highly enriched. In the above screening process of the present invention, a strict sterile state must be ensured. The ER2738 strain is tetracycline-resistant. In order to ensure the growth of specific strains rather than wild-type strains, thereby screening out polypeptides with strong characteristics and affinity, tetracycline is added to the culture medium used in the screening process of the present invention. Sub-inhibitory concentrations of tetracycline are used to continuously induce resistance in wild-type Escherichia coli (sensitive strain) to prevent phages from infecting non-target strains and causing false positive results.
[0097] Example 2
[0098] This embodiment provides an IDO1 protein degradation targeting chimera, denoted as IDO1-PROTAC, with a structural schematic diagram as shown in Figure 1 As shown, it is mainly prepared from the polypeptide targeting IDO1 of Example 1, thalidomide, a linker, a cell-penetrating peptide R8 and lysine. Among them, the linker is PEG2. When synthesizing IDO1-PROTAC in this embodiment of the present invention, it is handed over to Shanghai Chupeptide Biotechnology Co., Ltd. for biosynthesis according to the following structure.
[0099] The specific structure of the IDO1 protein degradation targeting chimera is as follows:
[0100]
[0101] Among them, for ease of understanding, the positions of the IDO1-targeting peptide, thalidomide, linker, transmembrane peptide R8, and lysine in IDO1-PROTAC are shown in the following formula:
[0102]
[0103] Experimental Example 1: Preliminary identification of the binding of polypeptide Q1 to IDO1 protein using enzyme-linked immunosorbent assay (ELISA)
[0104] The test method is:
[0105] 1) Immobilize IDO1 protein on the ELISA plate, same as step 1-1;
[0106] 2) Count the blue plaques on the titer plate and determine the phage titer at 1013-14 pfu / mL, dilute the eluate after the second round of panning and amplification (containing phages enriched with peptide Q1) to the same order of magnitude, use this value to calculate the input volume corresponding to the ELISA input titer, incubate at room temperature for 1-2h, quickly wash each plate 6 times with TBST buffer (TBS + 0.1% (v / v) Tween-20), and pour out the solution each time with a clean paper towel facing down;
[0107] 3) Add 100uL of 0.1-0.4ug / mL phage antibody to each well, incubate at room temperature for 1h, and quickly wash each well 6 times with TBST buffer, pouring out the solution with the well face down with a clean paper towel each time;
[0108] 4) Add 100uL of color development solution to each well and incubate at room temperature in the dark for 30 minutes;
[0109] 5) Add 50uL of stop solution to each well and measure the value with a 450nm wavelength using an ELISA reader. The result is as follows Figure 2 shown.
[0110] The present invention uses Elisa test to preliminarily detect whether the polypeptide Q1 in the complex mixture enriched by two rounds of panning binds to the IDO1 protein. In the figure, Target seq refers to the polypeptide Q1 sequence. Figure 2 It can be seen that compared with the control, the peptide Q1 in the complex mixture enriched by two rounds of panning binds to IDO1.
[0111] Experimental Example 2: Using BLI Biomembrane Interferometry to Explore the Binding Kinetics of Peptides Q1, Q8 and IDO1
[0112] Bio-layer interferometry (BLI) is an experimental method for detecting molecular interactions based on the displacement changes of interference spectra. When different biomolecules combine with ligands on the sensor surface, biofilms of different thicknesses and densities will be formed on the sensor surface, and the interference spectra generated by visible light on the membrane surface will also change accordingly, thereby accurately measuring the interaction process between the molecules to be tested. In order to evaluate the binding affinity of Q1 and Q8 polypeptides with IDO1 protein at the molecular level, the present invention modifies the N-termini of Q1 and Q8 polypeptides with biotin, respectively, solidifies Q1 polypeptide and Q8 polypeptide on SA sensors, and passes the sensors through a concentration gradient of IDO1 protein solution, i.e., performs binding kinetics experiments on the BLI molecular interaction instrument.
[0113] The experimental process of BLI biofilm interferometry technology is as follows:
[0114] 1) Place the SA sensor in a pre-wetted plate for 5 minutes, dilute the synthesized Q1 peptide carrying a biotin tag to 100 nmol / L with 0.1 mol / L NaHCO3, pH 8.6 solution, take 200 μL and add it to a black 96-well plate, and set up a blank SA probe and a negative control group without peptide buffer. Set the running program (Baseline 60s, Loading 3600s, Baseline 60s) on the BLI molecular interaction instrument to solidify the Q1 peptide carrying a biotin tag on the SA sensor;
[0115] 2) Add 0.02% Tween-20 to 0.1 mol / L NaHCO3, pH 8.6 solution, and use this solution to dilute the purified IDO1 catalytic domain protein from 50 μmol / L down to five concentration gradients by 10 times, and add them to a black 96-well plate in order from low to high concentration. At the same time, set up a negative control group without adding peptide buffer, set the operating program (Baseline 60s, Association 180s, Disassociation 180s) on the BLI molecular interaction instrument, and cycle once for each concentration;
[0116] 3) Data processing: export the results to Graphpad to calculate the KD value and draw the binding and dissociation curve. The results are as follows Figure 3a~3d shown.
[0117] in, Figure 3a and Figure 3c The results show that the binding and dissociation curves of Q1 peptide and IDO1 show a trend of fast binding and slow dissociation. The average response signals obtained at different concentrations were further fitted with curves. Figure 3b and Figure 3d is the KD value and fitting curve constant R calculated in Graphpad 2 The above experimental results show that the Q1 polypeptide has good binding affinity with the IDO1 protein in vitro. The Q8 polypeptide has relatively weak binding affinity with the IDO1 protein.
[0118] Experimental Example 3: IP experiment verifies the binding of peptide to IDO1 extracellular domain protein
[0119] Although it has been proven that Q1 peptide has good binding affinity, the targeting of Q1 peptide to IDO1 still needs to be explored. In order to prove the targeting of Q1 peptide to IDO1, Q1 peptide with biotin tag was combined with streptavidin magnetic beads to make it act as a "bait" to bind to IDO1.
[0120] Experimental steps: 1) Take 20μL streptavidin magnetic beads, wash them three times with RIPA lysis buffer, and use a magnetic stand to perform magnetic separation to wash off the magnetic bead protective solution. 2) Add 10μM Q1 polypeptide with a biotin label, incubate on a rotating shaker at room temperature for two hours to couple the Q1 polypeptide to the streptavidin magnetic beads for subsequent target protein capture. After the incubation, discard the supernatant, wash the magnetic beads three times with RIPA lysis buffer to remove unbound Q1 polypeptide. 3) One group added purified IDO1 catalytic domain protein solution, and the other group added MGC803 gastric cancer cell lysate, incubated on a rotating shaker at room temperature overnight, discarded the supernatant, washed the magnetic beads three times with RIPA lysis buffer to remove unbound proteins. 4) Add 50μL pH3.0 eluent, perform magnetic separation on a magnetic stand, transfer to a new EP tube, add SDS-PAGE protein loading buffer for denaturation, and use Western blot to analyze the experimental results. The results are as follows. Figure 4 shown.
[0121] Depend on Figure 4 It can be seen that the Q1 peptide successfully binds to the IDO1 catalytic domain protein, proving that the Q1 peptide has targeting to IDO1 at the molecular level. In addition, the MGC803 gastric cancer cell lysate treated with the Q1 peptide was incubated with streptavidin magnetic beads again, proving that the Q1 peptide can also target IDO1 in gastric cancer cells. In addition, IgG is used as a negative control antibody to detect nonspecific binding. Ideally, IgG should not bind to any target protein, so there is no band or only a very weak band in the IgG lane.
[0122] Experimental Example 4: Evaluation of IDO1-PROTAC in vitro biological activity
[0123] The present invention has confirmed that the Q1 polypeptide has good binding affinity and targeting to IDO1 at both the molecular level and the cellular level. On this basis, the Q1 polypeptide was used as the target protein ligand of IDO1, and the IDO1-PROTAC, a polypeptide degrader targeting IDO1, of Example 2 was designed and synthesized, and its biological activity was evaluated in MGC803 gastric cancer cells.
[0124] The experiment selected protein immunoblotting (Western blot) to verify the IDO1-PROTAC concentration-dependent degradation experiment. The specific steps are as follows: 1) Take gastric cancer cells MGC803 in the logarithmic growth phase and add 7×10 6Cells were inoculated into 6-well plates at 100 μg / well. Different concentrations of the test compound diluted with complete medium were added to a final volume of 2 mL (final concentrations were 2 μM, 4 μM, 6 μM, 8 μM, 16 μM, and 32 μM), and the same volume of DMSO was used as a negative control group. After culturing for 24 h, the cells were collected and diluted to 1.5 mL 1) Place the sample in an EP tube, centrifuge at 3000rpm for 5min, and wash the cell pellet with PBS; 2) Add protein lysis buffer, lyse on ice for 30min, then centrifuge at 4℃ and 12000rpm for 15min, take the supernatant to a new EP tube, quantify the BCA protein, add SDS-PAGE protein loading buffer (6X) to the remaining supernatant, and boil it in a metal bath at 100℃ for 15min; 3) After the sample is cooled, perform SDS-PAGE electrophoresis, transfer to nitrocellulose membrane, block with 5% skim milk powder at room temperature for 2h, add IDO1 and GAPDH antibodies (diluted to 1000 times with 5% BSA respectively), incubate at 4℃ overnight, recover the antibody, wash (3×10min), add goat anti-rabbit IgG (diluted to 5000 times with PBST respectively), incubate at room temperature for 1h, wash (3×10min), add ECL developer, and expose the gel imager. The results are as follows: Figure 5 shown.
[0125] Depend on Figure 5 The Western blot results showed that IDO1-PROTAC showed a concentration-dependent degradation of IDO1 in MGC803 gastric cancer cells, that is, IDO1-PROTAC degraded IDO1 in a concentration-dependent manner, and the degradation was obvious at 8 μM.
[0126] Furthermore, the protein immunoblotting method was used to verify the time-dependent degradation experiment of IDO1-PROTAC. The specific steps are as follows: 1) Gastric cancer cells MGC803 in the logarithmic growth phase were taken and 7×10 61) Inoculate cells / well in a 6-well plate. Add the test compound diluted with complete medium to a final concentration of 8μM. Set different time points (4h, 8h, 16h, 24h, 48h), use the same volume of DMSO as the negative control group, collect cells into 1.5EP tubes, centrifuge at 3000rpm for 5min, and wash the cell pellet with PBS; 2) Add protein lysis buffer, lyse on ice for 30min, then centrifuge at 4℃ and 12000rpm for 15min, take the supernatant into a new EP tube, quantify the protein by BCA, add 6× loading buffer to the remaining supernatant, and boil in a metal bath at 100℃ for 15min. 3) After the sample was cooled, SDS-PAGE electrophoresis was performed and transferred to nitrocellulose membrane, blocked with 5% skim milk powder at room temperature for 2 hours, IDO1 and GAPDH antibodies (diluted to 1000 times with 5% BSA) were added, and incubated overnight at 4°C. The antibodies were recovered, washed (3×10 min), and goat anti-rabbit IgG (diluted to 5000 times with PBST) was added and incubated at room temperature for 1 hour. After washing (3×10 min), ECL developer was added and exposed on a gel imager. The results are shown in Figure 2. Figure 6 shown.
[0127] Figure 6 Western blot results showed that the degradation of IDO1 in MGC803 gastric cancer cells by IDO1-PROTAC was time-dependent and obvious within 48 hours.
[0128] In summary, the polypeptide targeting IDO1 provided by the present invention is a high-affinity and targeted IDO1 extracellular domain protein binding polypeptide successfully selected by phage display technology. The polypeptide has a strong binding force with the IDO1 extracellular domain structural protein, and has the characteristics of low cost, high sensitivity, high recognition efficiency and small molecular weight. The present invention further obtains PROTAC by rationally designing the above-mentioned polypeptide and the E3 ubiquitin ligase ligand thalidomide, which has good cell entry ability and IDO1 targeted degradation ability, and can make the therapeutic drugs for cancer diseases such as gastric cancer more selective, while reducing systemic toxicity. Provide higher therapeutic efficiency. Therefore, the present invention can provide a new treatment strategy and effective technical support for the development of new tumor targeted drugs and the treatment of related cancers such as gastric cancer.
Claims
1. A polypeptide targeting IDO1, characterized in that The amino acid sequence of the polypeptide targeting IDO1 is shown as SEQ ID No.
1.
2. A use of the polypeptide targeting IDO1 as claimed in claim 1, characterized in that: Application in the preparation of anti-tumor drugs.
3. The use of the polypeptide targeting IDO1 according to claim 2, characterized in that: The anti-tumor drug is an anti-gastric cancer drug.
4. An IDO1 protein degradation targeting chimera, characterized in that: The IDO1 protein degradation targeting chimera is mainly prepared from the IDO1 targeting polypeptide according to claim 1, thalidomide, a linker and a cell-penetrating peptide R8.
5. The IDO1 protein degradation targeting chimera according to claim 4, characterized in that: The linker is PEG2.
6. The IDO1 protein degradation targeting chimera according to claim 4, characterized in that: The raw materials used in the preparation of the IDO1 protein degradation targeted chimera also include lysine.
7. The IDO1 protein degradation targeting chimera according to claim 4, characterized in that: The structure of the cell-penetrating peptide R8 is:
8. The IDO1 protein degradation targeting chimera according to any one of claims 4 to 7, characterized in that: The structure of the IDO1 protein degradation targeting chimera is:
9. A use of the IDO1 protein degradation targeting chimera according to any one of claims 4 to 8, characterized in that: Application in the preparation of anti-tumor drugs.
10. The use of the IDO1 protein degradation targeting chimera according to claim 9, characterized in that: The anti-tumor drug is an anti-gastric cancer drug.
Citation Information
Patent Citations
IDO1 polypeptide nano inhibitor, preparation method and applications thereof
CN111035623A
STING agonist-IDO1 inhibitor composite nanoparticle as well as preparation and application thereof
CN116173222A
Cited By
Application of inhibiting substance of E3 ubiquitin ligase SYVN1 in preparation of medicine for treating gastric cancer
CN119679951A
Chimera for targeted degradation of immune protein as well as preparation method and application of chimera
CN119707950A
